Innovative approaches for the treatment of stroke: a recent update.

The domain of stroke therapy is indeed undergoing rapid advancement, characterized by the emergence of innovative strategies such as stem cell therapy, exosomes, and gene editing methodologies. Although existing treatments, including thrombolysis and endovascular interventions, have enhanced stroke outcomes, but are limited by challenges such as narrow therapeutic windows and potential adverse effects. Novel therapeutic approaches, particularly those incorporating stem cells-such as mesenchymal (MSCs), embryonic, and induced pluripotent (iPSCs)-are exhibiting considerable promise. These cellular entities and their derivatives have been shown to facilitate brain repair by diminishing inflammation and supporting the regeneration of neurons and blood vessels. Especially, exosomes which are capable of promoting tissue repair and neuroprotection without immune rejection have proven to be significant. Furthermore, gene editing technologies such as CRISPR/Cas9 provide avenues to augment stem cell therapies through the modification of genes implicated in stroke pathogenesis. For instance, the targeting of genes such as DAPK1, which are associated with cell death and neuronal injury post-stroke, may potentially enhance the survival and integration of transplanted stem cells, thereby contributing to improved functional recovery. Also, the use of organoid models has represented another cutting-edge research frontier, which provides a platform to study stroke pathophysiology and test potential therapies in a controlled environment, but challenges persist and hence factors such as the survival and differentiation of transplanted cells, the risk of immune rejection, and the necessity for standardized protocols require resolution. By bridging these gaps, the potential for more effective and regenerative stroke treatments will become a reality, paving the way for better patient outcomes.